Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Immunol. Nov 18, 2025; 15(1): 111119
Published online Nov 18, 2025. doi: 10.5411/wji.v15.i1.111119
Published online Nov 18, 2025. doi: 10.5411/wji.v15.i1.111119
Role of IgE cells in the exacerbation and management of asthma: An experimental study
Agussalim Agussalim, Department of Nursing, Makassar Health Polytechnic, Makassar 92152, Sulawesi Selatan, Indonesia
Citrawati Citrawati, Department of Midwifery, Makassar Health Polytechnic, Makassar 92152, Indonesia
Adriyani Adam, Department of Nutritionist, Makassar Health Polytechnic, Makassar 92152, Indonesia
Author contributions: Agussalim A contributed to conceptualization; project administration; methodology design; data curation; formal statistical analysis, manuscript drafting and critical revision; final approval of the manuscript; Citrawati C contributed to literature review; manuscript writing and editing, supervision of clinical data collection; Adam A contributed to oversight of laboratory and spirometry assessments, validation of immunologic assays, critical review of discussion and conclusion; proofreading and editing of the final version; all authors have read and approved the final manuscript and agree to be accountable for all aspects of the work.
Institutional review board statement: Approval from Health Research Ethics Committee–Poltekkes Kemenkes Makassar IRB Approval Number: EC/2785/2024.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest regarding the publication of this paper.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Data sharing statement: Data Sharing Statement: The data supporting the findings of this study are available from the corresponding author, Dr. Agussalim (salim170878@gmail.com), upon reasonable request. All shared data will be de-identified to protect participant confidentiality and will be provided solely for non-commercial academic and research purposes, following institutional and ethical approval.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Agussalim Agussalim, DNS, Assistant Professor, Department of Nursing, Makassar Health Polytechnic, Jalan Banta Bantaeng, Makassar 92152, Sulawesi Selatan, Indonesia. salim170878@gmail.com
Received: June 24, 2025
Revised: July 3, 2025
Accepted: October 29, 2025
Published online: November 18, 2025
Processing time: 146 Days and 19.8 Hours
Revised: July 3, 2025
Accepted: October 29, 2025
Published online: November 18, 2025
Processing time: 146 Days and 19.8 Hours
Core Tip
Core Tip: Asthma is a chronic respiratory disease driven in part by immune mechanisms involving IgE. This experimental study highlights the significant role of IgE in asthma exacerbation and demonstrates that anti-IgE therapy—specifically with omalizumab—can markedly reduce IgE levels, improve lung function, enhance asthma control, and decrease the frequency of exacerbations. These findings emphasize the clinical value of incorporating immunomodulatory strategies, particularly targeted anti-IgE interventions, into the treatment of moderate to severe allergic asthma.